Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Ampio Pharm

Healthcare US AMPE

0.1831USD
0.00(0%)

Last update at 2026-06-02T20:00:00Z

Day Range

0.00520.0052
LowHigh

52 Week Range

0.00010.30
LowHigh

Fundamentals

  • Previous Close 0.18
  • Market Cap0.29M
  • Volume334
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-9.39100M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-17.65

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -8.63200M -16.33700M -17.07500M -15.89400M -13.63000M
Minority interest - - - - -
Net income -8.63200M -8.46700M -12.48500M -16.49800M -8.68400M
Selling general administrative 7.08M 11.47M 8.67M 6.65M 5.90M
Selling and marketing expenses 0.13M - - - -
Gross profit -0.25000M - - - -
Reconciled depreciation 0.30M 1.05M 1.09M 1.18M 1.27M
Ebit -8.63200M -24.20700M -25.15700M -15.21800M -23.44500M
Ebitda -8.38200M -23.15900M -24.06300M -14.04100M -22.17300M
Depreciation and amortization 0.25M 1.05M 1.09M 1.18M 1.27M
Non operating income net other - - 3.49M -0.07200M 4.87M
Operating income -9.51800M -24.20700M -25.15700M -15.21800M -23.44500M
Other operating expenses 9.52M 20.38M 20.57M 15.83M 18.58M
Interest expense - -7.87000M 8.08M 0.00000M 0.08M
Tax provision - - - - -
Interest income 0.38M 0.22M 0.00400M 0.01M 0.08M
Net interest income 0.38M 0.22M 0.00400M 0.01M 0.08M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -7.87000M -4.59000M 0.60M -4.94600M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 9.27M 20.38M 20.57M 15.83M 18.58M
Cost of revenue 0.25M - - - -
Total other income expense net 0.89M 7.87M 8.08M -0.67600M 9.81M
Discontinued operations - - - - -
Net income from continuing ops -8.79800M -16.33700M -17.07500M -15.89400M -13.63000M
Net income applicable to common shares - -16.33700M -17.07500M -15.89400M -13.63000M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 5.74M 13.59M 38.83M 22.88M 14.00M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.73M 0.62M 0.53M 0.70M 0.56M
Total liab 2.38M 1.80M 11.54M 5.37M 7.56M
Total stockholder equity 3.36M 11.79M 27.28M 17.51M 6.44M
Deferred long term liab - - 5.80M 2.61M 2.06M
Other current liab 1.06M 0.76M 4.38M 1.36M 3.87M
Common stock - 0.00200M 0.02M 0.02M 0.02M
Capital stock 0.00000M 0.00200M 0.02M 0.02M 0.02M
Retained earnings -242.52700M -233.93900M -217.60200M -200.52700M -184.63300M
Other liab - 0.33M 5.80M 2.61M 2.06M
Good will - - - - -
Other assets - - 42.02M - -
Cash 4.09M 12.65M 33.89M 17.35M 6.53M
Cash and equivalents - - - - -
Total current liabilities 2.38M 1.19M 5.12M 1.83M 4.28M
Current deferred revenue - - - - -
Net debt -3.81500M -12.03900M -32.96700M -16.13700M -5.06300M
Short term debt 0.55M 0.34M 0.31M 0.28M 0.26M
Short long term debt - - - - -
Short long term debt total 0.27M 0.61M 0.93M 1.21M 1.47M
Other stockholder equity 245.89M 245.73M 244.86M 218.02M 191.06M
Property plant equipment - 0.26M 2.56M 3.56M 4.75M
Total current assets 5.74M 13.33M 35.63M 18.49M 8.25M
Long term investments - - - - -
Net tangible assets - 11.79M 27.28M 17.51M 6.44M
Short term investments 0.00003M - - - -
Net receivables 0.92M - 0.02M 0.18M 0.02M
Long term debt - - - - -
Inventory 0.00000M 0.00000M 1.19M 0.27M -
Accounts payable 0.75M 0.10M 0.43M 0.19M 0.15M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -6.06500M
Additional paid in capital - - - - -
Common stock total equity - - 0.02M 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - - -217.60200M -200.52700M -184.63300M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.14M - 0.63M 0.82M 1.00M
Deferred long term asset charges - - - - -
Non current assets total 0.14M 0.26M 3.19M 4.38M 5.75M
Capital lease obligations 0.27M 0.61M 0.93M 1.21M 1.47M
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 0.00000M 0.00000M -0.09700M -0.06300M -0.02200M
Change to liabilities - -3.95900M 3.26M -2.47500M 2.70M
Total cashflows from investing activities - - -0.09700M -0.06300M -0.02200M
Net borrowings - - - - -
Total cash from financing activities 0.10M -0.11100M 30.73M 25.61M 14.35M
Change to operating activities - 0.98M -0.68200M 0.49M -1.34100M
Net income -8.63200M -16.33700M -17.07500M -15.89400M -13.63000M
Change in cash -8.56400M -21.23900M 16.55M 10.81M -1.05300M
Begin period cash flow 12.65M 33.89M 17.35M 6.53M 7.58M
End period cash flow 4.09M 12.65M 33.89M 17.35M 6.53M
Total cash from operating activities -8.56400M -21.12800M -14.08900M -14.72900M -15.38300M
Issuance of capital stock 0.10M 0.00000M 33.01M 26.19M 12.14M
Depreciation 0.12M 1.05M 1.09M 1.18M 1.27M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.92000M - - - -
Sale purchase of stock - - -0.18600M 0.79M 3.87M
Other cashflows from financing activities -0.09800M -0.11100M -2.09400M -0.58500M 2.21M
Change to netincome - -3.10400M -0.77700M 1.89M -4.45400M
Capital expenditures 0.00000M 0.00000M 0.10M 0.06M 0.02M
Change receivables - - - - -
Cash flows other operating - - -0.59300M 0.57M -1.27100M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 16.55M 10.81M -1.05300M
Change in working capital -1.23600M -2.97400M 2.58M -1.98500M 1.36M
Stock based compensation 0.16M 0.95M 2.72M 1.28M 0.41M
Other non cash items 1.02M -3.81800M 0.08M 0.62M 0.08M
Free cash flow -8.56400M -21.12800M -14.18600M -14.79200M -15.40500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
AMPE
Ampio Pharm		 - -% 0.18 - - - 0.10 0.45
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. The company develops OA-201, a small molecule formulation for the treatment of OAK pain. Ampio Pharmaceuticals, Inc. is based in Englewood, Colorado.

Ampio Pharm

9800 Mount Pyramid Court, Englewood, CO, United States, 80112

Key Executives

Name Title Year Born
Mr. Michael A. Martino CEO & Director 1957
Dr. David Bar-Or M.D. Founder & Chairman of Scientific Advisory Board 1949
Mr. Daniel G. Stokely CPA, CPA CFO, Corp. Sec. & Treasurer 1964
Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D. Chief Medical Officer 1954
Lane Hapke VP of Manufacturing Operations NA
April Ramirez Clinical Trial Mang. NA
Laura Goldberg VP of Quality and Regulatory Operations NA
Mr. Michael A. Martino CEO, CFO, General Secretary & Director 1957
Ms. April Ramirez Clinical Trial Manager NA
April Ramirez Clinical Trial Manager NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.